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Mouse
Liver
KidneyMutations in ABCC6 (ATP-binding cassette, subfamily C, member 6), an orphan transporter
expressed in the liver, are the cause of pseudoxanthoma elasticum. Since ABCC6 was reported to
affect matrix Gla protein (MGP), an inhibitor of bone morphogenetic proteins (BMPs), we studied
BMP signaling and expression in various tissues of mice with and without functional ABCC.
Enhanced BMP signaling was found in all examined tissues in the absence of ABCC6. Despite this,
the expression of particular BMP proteins varied widely between tissues. Interestingly, the expres-
sion of most BMP proteins in the liver moved in the opposite direction to the same BMP proteins in
kidneys in response to ABCC6 alterations. Thus, ABCC6 deﬁciency stimulates BMP signaling by acting
on the expression of multiple BMPs.
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is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction calciﬁcation [6]. Previous work on ABCC6 deﬁciency suggests thatABCC6 (ATP-binding cassette, subfamily C, member 6) is an
orphan transporter mainly expressed in the liver [1]. Mutations
in the human ABCC6/MRP6 gene is a known cause of pseu-
doxanthoma elasticum (PXE) [2], a heritable recessive disorder
characterized by calciﬁcation of elastin ﬁbers in connective tissue,
including the heart, vasculature, skin and eyes [3]. In addition to
vascular calciﬁcation [4], the mice with Abcc6 mutations also
exhibit other vascular abnormalities including lower elasticity
and increased myogenic tone [5]. It is believed that the ABCC6
substrate mediates the ectopic calciﬁcation via the circulation
since ABCC6 is absent or minimally expressed in the calciﬁed tissue
resulting from the deﬁciency. This is consistent with the ﬁnding
that parabiotic combination of blood circulation between Abcc6
knockout (Abcc6/) and wild type mice rescued the vascularthe tissue effects are mediated by multiple signaling pathways
such as the transforming growth factor beta (TGFb) family and
bone morphogenetic proteins (BMPs) [7].
BMP signaling is a pro-mineralizing pathway that has been
associated with ABCC6 deﬁciency and could promote osteochon-
drogenic transitions in susceptible cells. Indeed, Hosen et al.
reported an up-regulation of the BMP2-SMADs-RUNX2 as well as
the TGFb2-SMAD2/3 pathways at the mineralization sites in
ABCC6-deﬁcent mice [7], and Meng et al. reported that ABCC6 cor-
related with the BMP2-Wnt signaling pathway [8]. Matrix Gla pro-
tein (MGP) acts as an inhibitor of BMP2, BMP4, BMP6 and BMP7
[9–11] (unpublished data for BMP6), and depends on correctly
gamma-carboxylated glutamate residues for optimal function
[10]. Low levels of gamma-carboxylation in MGP and low serum
levels of MGP have been reported in ABCC6 deﬁciency [12,13],
which might lessen the BMP inhibitory function of MGP. It has
also been reported that the gamma-carboxylation system in the
vasculature is less efﬁcient than in the liver [14], potentially
putting the vasculature at higher risk for calciﬁcation if
gamma-carboxylation is impaired. Our previous studies suggested
that BMP signaling is increased in the ABCC6-deﬁcient heart [15]
further supporting that BMP signaling is a downstream target of
ABCC6.
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we examined if ABCC6, mainly expressed in the liver, affected
BMP signaling in other organs, focusing on liver, kidneys, and
aorta, and if the same BMP-related genes were activated. We
found a general activation of BMP signaling in these organs in
the absence of ABCC6. However, the induction of BMP and their
receptors varied between tissues, making it difﬁcult to attribute
the BMP activation to a particular factor. We conclude that
although the presence (or absence) of genetic deﬁciency of
ABCC6 has a systemic effect on BMP signaling, but is caused by
tissue-speciﬁc induction of BMP-related genes. Targeting BMP
signaling for treatment purposes may therefore have to be tailored
to the respective organs.
2. Methods
2.1. Ethics statement
Use of animals and all experimental procedures were review
and approved by the University of California, Los Angeles (UCLA)
Chancellor’s Animal Research Committee (ARC). The investigation
conformed to the National Research Council, Guide for the Care
and Use of Laboratory Animals, Eighth Edition (Washington, DC:
The National Academies Press, 2011).
2.2. Animals and cells
C3H/HeJ (C3H) and C57BL/6J (BL6) mice were purchased from
the Jackson Laboratory. Abcc6-Tg mice on C3H background were
generated as described [8] and contain an Abcc6 BAC transgene
derived from C57BL/6J. Abcc6 knockout (Abcc6/) mice were
obtained from Dr. A.A.B. Bergen [4] and backcrossed for 10 genera-
tions on a C57BL/6J background. Littermates were used as wild
type controls. All mice were fed a standard chow diet (Diet 8604,
HarlanTeklad, Laboratory). All mice were used for experiments at
3–4 months of age.
Bovine aortic endothelial cells (BAEC) were cultured as pre-
viously described [16], and BMP4 (0–40 ng/ml, R&D Systems) in
culture medium with 10% fetal bovine serum (FBS), or serum from
C3H or C3H-Abcc6Tg mice was added at the time of plating.
2.3. RNA analysis
Quantitative (q)PCR was performed as previously described
[16,17]. The primers and probes used for qPCR for mouse activin
receptor-like kinase (ALK) 1, ALK2, BMP2, BMP4, BMP6, BMP7, heat
shock protein (HSP)70, MGP, Noggin, and crossveinless-2 (CV2)
were pre-designed and obtained from Applied Biosystems (Foster
City, CA) as part of Taqman Gene Expression Assays.
2.4. Immunoﬂuorescence
Tissue sections were ﬁxed in 4% paraformaldehyde and pro-
cessed as previously described [18]. Immunoﬂuorescence was per-
formed in detail as previously described [19]. We used speciﬁc
antibodies for pSMAD1/5/8 (Santa Cruz Biotechnology), total
SMAD and ALK2 (both from Santa Cruz Biotechnology), ABCC6
(MRP6 antibody S-20, Santa Cruz Biotechnology), albumin
(Bethyl Laboratories). The nuclei were stained with 40,6-diami-
dino-2-phenylindole (DAPI) (Sigma–Aldrich) [19].
2.5. Immunoblotting
Immunoblotting was performed as previously described [20].
Equal amounts of cellular protein or culture medium were used.
Results were then analyzed by immunoblotting using speciﬁcantibodies to VEGF (200 ng/ml; R&D Systems). Blots were incu-
bated with speciﬁc antibodies to pSMAD1/5/8, pSMAD2/3 (both
400 ng/ml; Cell Signaling Technology), total SMAD, BMP-4, ALK1,
ALK2, (all 400 ng/ml; Santa Cruz Biotechnology), BMP-2, ALK3
and ALK6 (all 200 ng/ml; Santa Cruz Biotechnology), BMP-6,
BMP-7, BMP receptor type II (BMPRII), CV2, and Noggin (all
200 ng/ml; R&D Systems), HSP70 (100 ng/ml; Stressgen). b-Actin
(1:5000 dilution; Sigma–Aldrich) was used as loading control.
2.6. Statistical analysis
Data was analyzed for statistical signiﬁcance by ANOVA with
post hoc Tukey’s analysis. The analyses were performed using
GraphPad Instat, version 3.0 (GraphPad Software). Data represent
mean ± SD. P-values less than 0.05 were considered signiﬁcant, and
experiments were repeated a minimum of three times.
3. Results
3.1. ABCC6 deﬁciency is associated with BMP activation in multiple
organs
Previous observations suggested that BMP signaling increased
in ABCC-deﬁcient hearts [15]. Therefore, we hypothesized that
deﬁciency of ABCC, which is expressed mainly in the liver, had
the ability to affect BMP signaling also in other organs.
To study BMP signaling, we used C3H wild type mice, which
lack functional ABCC6 due to a natural mutation [21], and Abcc6
transgenic mice on the same background (C3H-Abcc6Tg mice).
The expression of ABCC6 in liver was about 0.03-fold and 3-fold
in C3H and C3H-Abcc6Tg mice, respectively, compared to BL6 mice,
which express functional ABCC6 as previously reported [8]. We
were able to detect ABCC6 by immunoﬂuorescence in the liver of
the C3H-Abcc6Tg and BL6 mice, but not in the C3H mice (Fig. 1A).
Albumin staining is shown for comparison. We were unable to
detect ABCC6 expression in other organs by immunoﬂuorescence
including kidneys (Fig. 1B), aorta, heart, muscle and lungs (data
not shown). We then compared BMP activity in these organs,
which revealed that liver, kidneys, heart, aorta, lungs, and muscle
all had increased levels of activated phosphorylated (p)SMAD1/5/8
as determined by immunoblotting (Fig. 2A). No changes were
detected in the levels of pSMAD2/3, which mediates TGFb-signal-
ing, or the levels of total SMAD proteins. To conﬁrm these results,
we used BL6 wild type mice and BL6 mice with Abcc6 gene
deletion (Abcc6/ mice). As expected, the BL6 mice had less
pSMAD1/5/8 in the tested organs when compared to BL6-Abcc6/
mice (Fig. 2B). In all subsequent experiments, we included the
BL6 to ensure consistency with the C3H-Abcc6Tg mice.
We also compared the ability of serum from C3H and C3H-
Abcc6Tg mice to enhance BMP4 signaling in BAECs. The BAECs were
treated for 20–24 h with BMP4 (0–40 ng/ml) in culture medium
containing 10% FBS, or serum from C3H or C3H-Abcc6Tg mice. The
levels of pSMAD1/5/8 were compared by immunoblotting. The
results showed that the serum from the C3H-Abcc6Tg mice caused
less activation of SMAD1/5/8 in response to BMP4 than did C3H
serum or FBS (Fig. 2C). Together, the results suggest that functional
ABCC6 regulates BMP signaling in the organs that were tested,
even though ABCC6 expression was only detected in the liver.
3.2. Altered expression of ALK2 in presence of the Abcc6 transgene
To further examine the BMP activation, we ﬁrst assessed the
expression of ALK2, a type I BMP receptor, in the heart, aorta, mus-
cle, kidneys, lungs and liver of C3H, C3H-Abcc6Tg, and wild type BL6
mice. ALK2 is widely expressed and can regulate expression of
MGP through the ALK1 receptor [22]. The results revealed that
Fig. 1. ABCC6 expression in C3H mice without and with an Abcc6 transgene. (A) Expression of ABCC6 was not detected in the liver of C3H mice (upper panels), but was
detected (green staining) in the liver of C3H-Abcc6Tg mice (middle panels) and BL6 mice (lower panels). Albumin (red staining) is shown for comparison. DAPI (blue) was used
to visualize the cell nuclei. (B) Expression of ABCC6 was not detected in the kidney in C3H, C3H-Abcc6Tg, or BL6 mice. Tissues from 2 to 3 sets of mice were stained with similar
results.
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the C3H-Abcc6Tg mice and the BL6 mice, both with functional
ABCC6. However, the liver showed the opposite pattern, with sig-
niﬁcant decreases in ALK2 in the presence of the Abcc6 transgene,
as determined by qPCR and immunoblotting (Fig. 3A and B). The
difference in ALK2 expression was also conﬁrmed by immunoﬂuo-
rescence in liver and kidneys (Fig. 3C).
3.3. Differential effects on expression of BMP components in liver and
kidneys
Because of the drastic changes in ALK2 expression in kidneys
and liver, we focused further experiments on these two organs.
We conﬁrmed that pSMAD1/5/8 levels were decreased in both of
the organs from the C3H-Abcc6Tg mice by immunoﬂuorescence
(Fig. 4A). We then investigated the expression of the BMPs
(BMP2, 3, 6, and 7), which are inhibited by MGP, and the BMP
receptors (ALK1, 2, 3, and 6, and BMPRII). We compared expression
in the C3H mice with that of the C3H-Abcc6Tg mice and BL6 mice
using immunoblotting. The results showed different patterns of
expression in kidneys and liver of the BMPs and BMP receptors.
All of these proteins, except BMP2, increased in the kidneys but
decreased or remained about the same in the liver (Fig. 4B).
BMP2, on the other hand, decreased in the kidneys and increased
in the liver (Fig. 4B). The expression was similar when examined
by qPCR, as shown for ALK1 and BMP2 (Fig. 4C), supporting the dif-
ferent patterns of expression of BMPs and their receptors in kid-
neys versus liver.
We also studied select modulators of BMP activity, including
CV2, a BMP inhibitor that may act in tandem with MGP [23], and
HSP70, an inﬂammatory protein that enhances BMP activity by
binding to MGP [24]. Similar to BMP2, CV2 decreased in the
kidneys and increased in the liver when ABCC6 was functional,
whereas HSP70 decreased in both organs (Fig. 4). Despite
these changes, the overall pSMAD1/5/8 levels increased similarly
in both organs in the absence of functional ABCC6 as described
above.
3.4. Effect on expression of BMP components in aorta
Since lack of ABCC6 has been implicated in vascular calciﬁca-
tion, we also examined expression of BMPs, BMP receptors and
modulators in the aorta. Again, we compared expression in theC3H mice with that of C3H-Abcc6Tg mice and BL6 mice using
immunoblotting. The results were less dramatic than in the liver
and kidneys, but showed mild increases in BMP-2, -4, and -6 (but
not BMP-7) associated with the enhanced ABCC6 levels
(Fig. 5A, B), similar to the kidney pattern. Interestingly, it is the
opposite of what would be expected considering that vascular cal-
ciﬁcation is associated with ABCC6-deﬁcient vessels. Therefore, we
also looked at the expression of HSP70, MGP, Noggin and CV2 using
qPCR. The results showed a mild decrease in HSP70, and mild
increases in MGP and Noggin (Fig. 5B and C), which might be
enough to limit the BMP activity and protect against calciﬁcation,
although further studies would be needed to prove this. We were
unable to obtain immunoblots for MGP due to unavailability of
appropriate antibodies. No signiﬁcant change was seen in CV2
expression (Fig. 5A and B).
4. Discussion
We examined the effect of ABCC6 deﬁciency on BMP activation
and BMP expression in several organs. Together, our results sug-
gest that functional Abcc6, detectable only in the liver in this study,
limits BMP activation in all organs studied based on the levels of
pSMAD1/5/8. However, the respective expression proﬁles of
BMPs, and BMP receptors and modulators differ between organs,
with mostly opposite effects in the liver versus the kidneys. Thus,
it is an example of a widespread, systemic effect on one pathway,
BMP signaling, which may cause different pathologies depending
on the tissue. The ABCC6 effects are likely to be affected by the
genetic context in various mouse strains, as already shown by
the identiﬁcation of ABCC6 as the Dyscalc1 locus [8].
It is not clear why we did not detect ABCC6 by immunoﬂuores-
cence in the liver and the heart of the C3H mice, even though
Aherrahrou et al. [21] detected ABCC6 in the liver by immunoblot-
ting, and Meng et al. [8] detected ABCC6 by qPCR. It is possible that
low levels of ABCC6 protein was not detected by the ABCC6
antibodies use in this study.
Alterations in BMP signaling are likely to contribute to the
effects of ABCC6 deﬁciency in cardiovascular system since BMPs
have been associated with hypertension, non-laminar ﬂow,
endothelial inﬂammation, angiogenesis, and calciﬁcation in the
vascular wall as well as the myocardium [15,25–29]. It may also
be instrumental in causing pathological changes in skin and eyes,
based on previous report demonstrating the importance of BMP
Fig. 2. ABCC6 deﬁciency in C3H and BL6-Abcc6/ mice is associated with BMP activation in multiple organs. (A and B) Phosphorylated (p)SMAD1/5/8 and pSMAD2/3 in heart,
muscle, aorta, kidneys, lungs, and liver from (A) C3H and C3H-Abcc6Tg mice and (B) BL6 and BL6-Abcc6/ mice, as determined by immunoblotting and compared to total
SMAD (n = 3 for each mouse strain). (C) PSMAD1/5/8 and pSMAD2/3 in bovine aortic endothelial cells treated with increasing concentrations of BMP4 (0–40 ng/ml) together
with 10% FBS, serum from C3H or serum from C3H-Abcc6Tg mice for 24 h, as determined by immunoblotting and compared to total SMAD (n = 3 for each mouse strain).
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SMADs-Runx2 signaling has been shown to co-localize with
mineralization sites in vibrissae and eyes in Abcc6/ mice and in
human PXE dermis [7]. There is also an upregulation of BMP2,
Runx2 and SMADs in PXE ﬁbroblasts compared to healthy controls
[7]. Overall, our ﬁndings of enhanced BMP activity in absence of
ABCC6 are consistent with previously reported ﬁndings.
Our studies are also consistent with previous reports suggesting
that ABCC6 in the liver affects other organs at a distance, possibly
through a circulating mediator(s). However, the identity and how
this putative mediator relates to BMP signaling requires additional
research, and is outside the scope of this study. The difﬁculty of
ﬁnding this putative mediator may be substantial considering
there is still an ongoing discussion of where ABCC6 is located in
the cell [32,33] in the mitochondria-associated membranes orthe plasma membrane. However, several candidate factors have
been identiﬁed by other authors, in particular pyrophosphate, a
potent inhibitor of vascular calciﬁcation that recently was shown
been to be decreased in Abcc6/ mice [34,35]. Other investigators
have shown that BMP2 can regulate phosphate uptake [36], and
that phosphate levels can regulate BMP2 expression [37].
However, it is not clear how pyrophosphate may mediate other
ABCC6 effects besides calciﬁcation.
Thus, our results suggest that although ABCC6 deﬁciency acti-
vates BMP signaling in multiple organs, the pattern of expression
for each BMP component varies. It further suggests that BMP
activation is coordinated between different organs, possibly
through circulating mediators, and that the organ-speciﬁc context
determines the effect of ABCC6. The systemic activation of BMP
may in part help explain the different features of pseudoxanthoma
Fig. 3. Altered expression of ALK2 in presence of the Abcc6 transgene in C3H mice.
(A and B) Expression of ALK2 in liver, lungs, kidneys, aorta, heart and muscle in C3H
mice (without functional ABCC6) and in C3H-Abcc6Tg and BL6 mice (both with
functional ABCC6), as determined by qPCR (expression is shown relative to that of
C3H, which is set at 1) (A) and immunoblotting (B) (n = 3 for each mouse strain for
qPCR and immunoblotting, respectively). Asterisks indicate statistically signiﬁcant
differences compared to C3H. ⁄⁄⁄<0.001, Tukey’s test. (C) Expression of ALK2 in liver
and kidneys (green), as determined by immunoﬂuorescence. Tissues from 2 to 3
sets of mice were stained with similar results.
Fig. 4. Differential effects on expression of BMP components in liver and kidneys by
functional ABCC6. (A) BMP activity in liver and kidney from C3H, C3H-Abcc6Tg, and
BL6 mice, as determined by immunoﬂuorescence for pSMAD1/5/8 (upper panels),
and compared to total SMAD (lower panels). Tissues from 2 to 3 sets of mice were
stained with similar results. (B) Expression of BMPs, BMP receptors and modulators
in liver and kidney from C3H, C3H-Abcc6Tg, and BL6 mice, as determined by
immunoblotting. b-Actin was used as loading control (n = 3 for each mouse strain).
(C) Expression of BMP2 (top) and ALK1 (bottom) in liver and kidney, from C3H and
C3H-Abcc6Tg mice, as determined by qPCR (expression is shown relative to that of
C3H, which is set at 1) (n = 3 for each mouse strain). Asterisks indicate statistically
signiﬁcant differences compared to C3H. ⁄<0.0, ⁄⁄⁄<0.001, Tukey’s test.
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expression, however, will have to be considered in targeting the
BMP signaling for potential treatments. The exact nature of the link
between ABCC6 function and BMP signaling is not clear and will
require more research. Further studies will also be required to
identify transcription factors that might coordinate the effect of
ABCC6 on gene expression.
Fig. 5. Effect on expression of BMP components in the aorta by functional ABCC6. (A) Expression of BMPs, BMP receptors, and BMP modulators in aortas from C3H, C3H-
Abcc6Tg, and BL6 mice, as determined by immunoblotting. b-Actin was used as loading control. (B and C) Expression of BMPs (B) and BMP modulators (C) in aortas from C3H,
C3H-Abcc6Tg, and BL6 mice, as determined by qPCR (expression is shown relative to that of C3H, which is set at 1) (n = 3 for each mouse strain for qPCR and immunoblotting,
respectively). Asterisks indicate statistically signiﬁcant differences compared to C3H. ⁄<0.0, ⁄⁄<0.01, ⁄⁄⁄<0.001, Tukey’s test.
262 A.M. Blazquez-Medela et al. / FEBS Open Bio 5 (2015) 257–263Author contribution statement
K.I. B, Y. Y conception and design; A.J. L contributed reagents;
A. B.-M Collection and assembly of data; A. B.-M , P. G, J, Y, M. J,
K. B, Y. Y data analysis and interpretation; A. B.-M., K.I. B, Y. Y
manuscript writing; A.J. L, K.I. B, Y. Y ﬁnancial support.
Acknowledgements
Funding: this work was supported by National Institutes of
Health Grants R01 HL81397 (to K.I. B), R01 HL112839 (to K.I. B),
R01 NS79353 (to Y. Y), and P1 HL30568 (to K.I. B, A.J. L).
References
[1] Beck, K., Hayashi, K., Nishiguchi, B., Le Saux, O., Hayashi, M. and Boyd, C.D.
(2003) The distribution of Abcc6 in normal mouse tissues suggests multiple
functions for this ABC transporter. J. Hisochem. Cytochem. 51, 887–902.
[2] Le Saux, O. et al. (2000) Mutations in a gene encoding an ABC transporter cause
pseudoxanthoma elasticum. Nat. Genet. 25, 223–227.
[3] Plomp, A.S., Toonstra, J., Bergen, A.A., van Dijk, M.R. and de Jong, P.T. (2010)
Proposal for updating the pseudoxanthoma elasticum classiﬁcation systemand a review of the clinical ﬁndings. Am. J. Med. Genet. Part A 152A, 1049–
1058.
[4] Gorgels, T.G. et al. (2005) Disruption of Abcc6 in the mouse: novel insight in
the pathogenesis of pseudoxanthoma elasticum. Hum. Mol. Genet. 14, 1763–
1773.
[5] Kauffenstein, G. et al. (2014) Disseminated arterial calciﬁcation and enhanced
myogenic response are associated with abcc6 deﬁciency in a mouse model of
pseudoxanthoma elasticum. Arterioscler. Thromb. Vasc. Biol. 34, 1045–1056.
[6] Jiang, Q., Oldenburg, R., Otsuru, S., Grand-Pierre, A.E., Horwitz, E.M. and Uitto, J.
(2010) Parabiotic heterogenetic pairing of Abcc6//Rag1/ mice and their
wild-type counterparts halts ectopic mineralization in a murine model of
pseudoxanthoma elasticum. Am. J. Pathol. 176, 1855–1862.
[7] Hosen, M.J., Coucke, P.J., Le Saux, O., De Paepe, A. and Vanakker, O.M. (2014)
Perturbation of speciﬁc pro-mineralizing signalling pathways in human and
murine pseudoxanthoma elasticum. Orphanet. J. Rare Dis. 9, 66.
[8] Meng, H. et al. (2007) Identiﬁcation of Abcc6 as the major causal gene for
dystrophic cardiac calciﬁcation in mice through integrative genomics. Proc.
Natl. Acad. Sci. U.S.A. 104, 4530–4535.
[9] Wallin, R., Cain, D., Hutson, S.M., Sane, D.C. and Loeser, R. (2000) Modulation of
the binding of matrix Gla protein (MGP) to bone morphogenetic protein-2
(BMP-2). Thromb. Haemost. 84, 1039–1044.
[10] Yao, Y., Shahbazian, A. and Bostrom, K.I. (2008) Proline and gamma-
carboxylated glutamate residues in matrix Gla protein are critical for
binding of bone morphogenetic protein-4. Circ. Res. 102, 1065–1074.
[11] Yao, Y., Jumabay, M., Wang, A. and Bostrom, K.I. (2011) Matrix Gla protein
deﬁciency causes arteriovenous malformations in mice. J. Clin. Invest. 121,
2993–3004.
A.M. Blazquez-Medela et al. / FEBS Open Bio 5 (2015) 257–263 263[12] Hendig, D., Zarbock, R., Szliska, C., Kleesiek, K. and Gotting, C. (2008) The local
calciﬁcation inhibitor matrix Gla protein in pseudoxanthoma elasticum. Clin.
Biochem. 41, 407–412.
[13] Uitto, J., Li, Q. and Jiang, Q. (2010) Pseudoxanthoma elasticum: molecular
genetics and putative pathomechanisms. J. Invest. Dermatol. 130, 661–670.
[14] Wallin, R., Cain, D. and Sane, D.C. (1999) Matrix Gla protein synthesis and
gamma-carboxylation in the aortic vessel wall and proliferating vascular
smooth muscle cells – a cell system which resembles the system in bone cells.
Thromb. Haemost. 82, 1764–1767.
[15] Mungrue, I.N. et al. (2011) Abcc6 deﬁciency causes increased infarct size and
apoptosis in a mouse cardiac ischemia-reperfusion model. Arterioscler.
Thromb. Vasc. Biol. 31, 2806–2812.
[16] Yao, Y., Zebboudj, A.F., Shao, E., Perez, M. and Bostrom, K. (2006) Regulation of
bone morphogenetic protein-4 by matrix GLA protein in vascular endothelial
cells involves activin-like kinase receptor 1. J. Biol. Chem. 281, 33921–33930.
[17] Jumabay, M. et al. (2012) Endothelial differentiation in multipotent cells
derived from mouse and human white mature adipocytes. J. Mol. Cell. Cardiol.
53, 790–800.
[18] Qiao, J.H., Xie, P.Z., Fishbein, M.C., Kreuzer, J., Drake, T.A., Demer, L.L. and Lusis,
A.J. (1994) Pathology of atheromatous lesions in inbred and genetically
engineered mice. Genetic determination of arterial calciﬁcation. Arterioscler.
Thromb. 14, 1480–1497.
[19] Bostrom, K.I., Jumabay, M., Matveyenko, A., Nicholas, S.B. and Yao, Y. (2010)
Activation of vascular bone morphogenetic protein signaling in diabetes
mellitus. Circ. Res. 108, 446–457.
[20] Bostrom, K., Tsao, D., Shen, S., Wang, Y. and Demer, L.L. (2001) Matrix GLA
protein modulates differentiation induced by bone morphogenetic protein-2
in C3H10T1/2 cells. J. Biol. Chem. 276, 14044–14052.
[21] Aherrahrou, Z. et al. (2008) An alternative splice variant in Abcc6, the gene
causing dystrophic calciﬁcation, leads to protein deﬁciency in C3H/He mice. J.
Biol. Chem. 283, 7608–7615.
[22] Yao, Y., Shao, E.S., Jumabay, M., Shahbazian, A., Ji, S. and Bostrom, K.I. (2008)
High-density lipoproteins affect endothelial BMP-signaling by modulating
expression of the activin-like kinase receptor 1 and 2. Arterioscler. Thromb.
Vasc. Biol. 28, 2266–2274.
[23] Yao, Y., Jumabay, M., Ly, A., Radparvar, M., Wang, A.H., Abdmaulen, R. and
Bostrom, K.I. (2012) Crossveinless 2 regulates bone morphogenetic protein 9
in human and mouse vascular endothelium. Blood 119, 5037–5047.
[24] Yao, Y., Watson, A.D., Ji, S. and Bostrom, K.I. (2009) Heat shock protein 70
enhances vascular bone morphogenetic protein-4 signaling by binding matrix
Gla protein. Circ. Res. 105, 575–584.[25] Miriyala, S., Gongora Nieto, M.C., Mingone, C., Smith, D., Dikalov, S., Harrison,
D.G. and Jo, H. (2006) Bone morphogenic protein-4 induces hypertension in
mice: role of noggin, vascular NADPH oxidases, and impaired vasorelaxation.
Circulation 113, 2818–2825.
[26] Sorescu, G.P. et al. (2003) Bone morphogenic protein 4 produced in endothelial
cells by oscillatory shear stress stimulates an inﬂammatory response. J. Biol.
Chem. 278, 31128–31135.
[27] Csiszar, A., Smith, K.E., Koller, A., Kaley, G., Edwards, J.G. and Ungvari, Z. (2005)
Regulation of bone morphogenetic protein-2 expression in endothelial cells:
role of nuclear factor-kappaB activation by tumor necrosis factor-alpha, H2O2,
and high intravascular pressure. Circulation 111, 2364–2372.
[28] David, L., Feige, J.J. and Bailly, S. (2009) Emerging role of bone morphogenetic
proteins in angiogenesis. Cytokine Growth Factor Rev. 20, 203–212.
[29] Bostrom, K.I., Rajamannan, N.M. and Towler, D.A. (2011) The regulation of
valvular and vascular sclerosis by osteogenic morphogens. Circ. Res. 109, 564–
577.
[30] Moura, J., da Silva, L., Cruz, M.T. and Carvalho, E. (2013) Molecular and
cellular mechanisms of bone morphogenetic proteins and activins in
the skin: potential beneﬁts for wound healing. Arch. Dermatol. Res. 305,
557–569.
[31] Wordinger, R.J. and Clark, A.F. (2007) Bone morphogenetic proteins and their
receptors in the eye. Exp. Biol. Med. 232, 979–992.
[32] Pomozi, V. et al. (2013) ABCC6 is a basolateral plasma membrane protein. Circ.
Res. 112, e148–e151.
[33] Martin, L.J. et al. (2012) ABCC6 localizes to the mitochondria-associated
membrane. Circ. Res. 111, 516–520.
[34] Dabisch-Ruthe, M., Kuzaj, P., Gotting, C., Knabbe, C. and Hendig, D. (2014)
Pyrophosphates as a major inhibitor of matrix calciﬁcation in Pseudoxanthoma
elasticum. J. Dermatol. Sci. 75, 109–120.
[35] Jansen, R.S. et al. (2014) ATP-binding cassette subfamily C member 6-
mediated ATP secretion by the liver is the main source of the mineralization
inhibitor inorganic pyrophosphate in the systemic circulation. Arterioscler.
Thromb. Vasc. Biol. 34, 1985–1989.
[36] Li, X., Yang, H.Y. and Giachelli, C.M. (2008) BMP-2 promotes phosphate uptake,
phenotypic modulation, and calciﬁcation of human vascular smooth muscle
cells. Atherosclerosis 199, 271–277.
[37] Tada, H., Nemoto, E., Foster, B.L., Somerman, M.J. and Shimauchi, H. (2011)
Phosphate increases bone morphogenetic protein-2 expression through
cAMP-dependent protein kinase and ERK1/2 pathways in human dental
pulp cells. Bone 48, 1409–1416.
